ARTICLE | Clinical News
BioInvent International A preclinical data
April 20, 2015 7:00 AM UTC
In mice, BI-1206 prevented tumor cell internalization of Rituxan rituximab, a chimeric mAb against CD20 antigen, and subsequently increased cell surface accessibility and immune effector cell-mediate...